Age: 21.0
Sex: F
Vaccine: FLU3, PPV, FLUX, PPV, FLUX, PPV
Symptoms: Injection site oedema, Leukocytosis, Local reaction, Local swelling, Pyrexia
Clinical narrative: This literature marketed report as received from a other health professional refers to a 21 year old female patient with asthma. This is case 2 of 5 reports. Patient's medical history was not reported. On an unknown date the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown) (dose and frequency unknown) in the arm. Other suspect therapies included influenza virus vaccine (Manufacturer unknown). The patient received both the vaccines in opposite arms. Patient's concomitant medication was not reported. On an unknown date the patient experienced large local inflammatory reactions (erythema, oedema and warmth) (hospitalization), fever (hospitalization), leucocytosis (hospitalization) presumed cellulitis (hospitalization) and vomiting (hospitalization). The patient's laboratory results included WBC 20.7K/microliter, ESR 92mm/hr, Maximum temperature 103.2 degree F and CRP 20mg/dl. The patient was admitted to the hospital, but did not receive antibiotics in hospital and post discharge from the hospital. The patient received the 2 vaccines in opposite arms, developed local erythema and edema at the site of the Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown). The arm where the influenza vaccine (manufacturer unknown) was placed was normal. This suggested that the local reaction experienced by the patients who received the Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown) and influenza vaccine (manufacturer unknown) in the same arm was due to the Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown) vaccine rather than the influenza vaccine. The patient sought care within 2-3 day of vaccination. Within 5-7 days, the patient experienced improvement in the skin findings and resolution of the systemic symptoms. In one patient, the local swelling and erythema at the injection site lasted about 2 weeks. The outcome of the events localized inflammation, injection site erythema, warmth and swelling and presumed cellulitis was considered resolving and outcome of fever, leucocytosis and vomiting was considered as resolved. The reporter considered the events to be not related to influenza virus vaccine (manufacturer unknown). The reporter considered the events to be related to Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown). The author stated that "the 5 patients in this series all had leukocytosis, fever and large local inflammatory reactions following influenza vaccine (manufacturer unknown) and Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown). Based on the known side effects of Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown), the lack of similar findings in patients who receive the influenza vaccine (manufacturer unknown) and the patient 2's lack of influenza vaccine (manufacturer unknown) associated local symptoms we believe these reactions were due to Pneumococcal Vaccine, Polyvalent (23-valent) (manufacturer unknown)". This case is linked to case # 1405USA008574, 1405USA007995, 1405USA008575 and 1405USA008576 (same reporter link).